

1955/12



THE DRUG TARIFF 1953, AMENDMENT NO. 6

PURSUANT to section 90 of the Social Security Act 1938, the Minister of Health hereby gives the following direction:

1. (1) This direction may be cited as the Drug Tariff 1953, Amendment No. 6, and shall be read together with and deemed part of the Drug Tariff 1953* (hereinafter referred to as the Drug Tariff).

(2) This direction shall come into force on the 1st day of March 1955.

2. (1) Clause 3 of the Drug Tariff is hereby amended by revoking the definition of the expression "British Pharmaceutical Codex", or "B.P.C.", and substituting the following definition:

"'British Pharmaceutical Codex', or 'B.P.C.', means the general monographs in Part I and the preparations specified in Part VI (the Formulary Section) of the British Pharmaceutical Codex 1954:'".

(2) Notwithstanding anything in subclause (1) of this clause, the expression "British Pharmaceutical Codex", or "B.P.C.", shall, until the end of September 1955, but not otherwise, include also the general monographs in Part I and the preparations specified in Part VI (the Formulary Section) of the British Pharmaceutical Codex 1949, together with the monographs set out in pages 1 to 81 inclusive and the amendments to Part VI specified in the Formulary Section of the 1952 Supplement to the British Pharmaceutical Codex 1949.

3. (1) The First Schedule to the Drug Tariff is hereby amended by revoking clause 8, and substituting the following clause:

"8. The following antibiotics, except to the extent specified in the Second Schedule or the Fourth Schedule hereto or in the New Zealand Formulary:

"Aureomycin hydrochloride.

"Chloramphenicol (chloromycetin).

"Oxytetracycline hydrochloride (terramycin).

"Tablets of penicillin for oral use (all strengths)."

*S.R. 1953/123.

Amendments Nos. 1 and 2: (*Revoked by Amendment No. 3*).

Amendment No. 3: S.R. 1954/119.

Amendment No. 4: S.R. 1954/192.

Amendment No. 5: S.R. 1955/8.

(2) The said First Schedule is hereby further amended by adding the following clause:

"14. The following materials, except to the extent specified in the Fourth Schedule or the Fifth Schedule hereto:

- "Cortisone acetate, and tablets of cortisone acetate.
- "Hexamethonium bromide.
- "Hexamethonium chloride.
- "Hexamethonium iodide.
- "Hexamethonium tartrate.
- "Pentamethonium iodide.
- "Tolazoline hydrochloride."

(3) Clause 13 of the said First Schedule is hereby amended by omitting the words "Pentamethonium iodide".

4. (1) The Second Schedule to the Drug Tariff is hereby amended by omitting from clause 1 the words "ten tablets", and substituting the words "sixteen tablets".

(2) The said Second Schedule is hereby further amended by inserting in clause 3, in their appropriate alphabetical order, the following items:

- "Benethamine penicillin for injection.
- "Benzathine penicillin for injection.
- "'Bifactor' tablets.
- "Capsules of synthetic vitamin K1 (konakion capsules).
- "Diphenmethanil methylsulphonate for injection (prantal).
- "'Marcoumar' tablets.
- "Oculentum tetracycline.
- "Solution of marphenide 5 per cent (sulphamar hydrochloride solution 5 per cent).
- "Tablets of acetazoleamide (diamox).
- "Tablets of chlormerodrin (merchloran tablets; neohydrin tablets).
- "Tablets of diphenmethanil methylsulphonate (prantal).
- "Tablets of methantheline bromide (banthine).
- "Tablets of pentaerythritol tetranitrate (peritrate).
- "Tablets of phenylindanedione (indema: dindevan).
- "Tablets of propantheline methobromide (pro-banthine).
- "Tablets of reserpine (serpasil), and such other alkaloids or preparations of rauwolfia serpentina as are approved from time to time by the Director-General of Health.
- "Tablets of triethanolamine trinitrate (praenitron).
- "Tablets of vitamins (strength identical with capsules of vitamins B.P.C.: multivite tablets).
- "Testosterone oenanthate for injection (primoteston depot)".

5. The Drug Tariff is hereby amended by revoking the Fourth Schedule (as substituted by clause 4 of the Drug Tariff 1953, Amendment No. 3) and the Fifth Schedule, and substituting the new Fourth and Fifth Schedules set out in the Schedule hereto.

6. The following enactments are hereby revoked, namely:

(a) Clauses 4, 5, and 8 of the Drug Tariff 1953, Amendment No. 3*, and the Schedule thereto.

(b) The Drug Tariff 1953, Amendment No. 4†.

*S.R. 1954/119.

†S.R. 1954/192.

SCHEDULE

NEW FOURTH AND FIFTH SCHEDULES TO THE DRUG TARIFF

“FOURTH SCHEDULE

Clause 5 (4)

MATERIALS INCLUDED IN THE DRUG TARIFF TO THE EXTENT, IF ANY, HEREIN SPECIFIED AND FOR THE PURPOSES HEREIN SPECIFIED, WHEN SUPPLIED ON A SPECIALLY ENDORSED PRESCRIPTION*

Name	Approved Purpose
1. ‘Hydergine’ ampoules	} Solely for use in the treatment of obliterative arteritis or of Raynaud’s disease.
‘Hydergine’ tablets (sublingual)	
Nicotinyl alcohol tartrate tablets 25 mg.	
Nicotinyl alcohol ampoules 100 mg. in 2 ml.	
(This drug is known under the trade name ‘Ronicol’)	
Tolazoline hydrochloride tablets 25 mg.	
Tolazoline hydrochloride ampoules 25 mg. in 1 ml.	} Solely on the prescription of an ophthalmologist.
(This drug is known under the trade name ‘Priscol’)	
2. Cortisone eye drops	
Cortisone eye ointment	
Hydrocortisone eye drops	} Solely for use in the treatment of chronic otitis media.
Hydrocortisone eye ointment	
3. Aureomycin otic solution 10 c.c. vial	} Solely for use in the treatment of chronic otitis media.
Chloromycetin otic solution 6 c.c. vial	
Terramycin otic solution 5 c.c. vial	

*NOTE.—A contractor shall not claim on the Fund in respect of any medical prescription ordering any one or more of the materials specified in this Schedule unless the prescription has been endorsed in the handwriting of the medical practitioner with the words ‘Certified Fourth Schedule condition’.

FOURTH SCHEDULE—continued

	Solely for use in the treatment of one or more of the following conditions:
	(1) Bacillary dysentery.
	(2) Acute amoebic dysentery.
	(3) Acute and sub-acute bacterial endocarditis.
	(4) Brucellosis.
	(5) Granuloma inguinale.
4. Subject to the restrictions on quantity specified at the end of this clause,—	(6) Lymphogranuloma venereum.
Aureomycin capsules or tablets	(7) Influenzal meningitis.
Aureomycin for injection	(8) Psittacosis and other virus infections of the psittacosis group.
Aureomycin oral suspension for children	(9) Salmonella infections.
Aureomycin spersoids	(10) Severe gastro-enteritis.
Aureomycin paediatric drops	(11) Pneumonia, where indicated.
Chloromycetin capsules	(12) Severe staphylococcal or other infections resistant to either penicillin or sulphonamides.
Chloromycetin palmitate	(13) Infections of the urinary tract, where indicated.
Chloromycetin paediatric drops	(14) Whooping cough, within the first week of the onset of symptoms.
Chloromycetin for injection	(15) Sensitivity to penicillin, where indicated.
Erythromycin tablets	
Erythromycin paediatric	
Terramycin capsules or tablets	
Terramycin for injection	
Terramycin oral suspension for children	
Terramycin paediatric drops	
As necessary, the corresponding preparations of "Achromycin" and "Tetracyclin", when prescribed	

Restrictions on quantity (clause 4): For the purposes of this clause—

- (a) In the case of capsules or tablets specified in this clause, the quantity for which payment may be made from the Fund pursuant to any one medical prescription shall not exceed sixteen capsules or tablets:
- (b) In the case of injections, oral suspensions, paediatric drops, or other preparations (other than capsules or tablets) specified in this clause, the quantity for which payment may be made from the Fund pursuant to any one medical prescription shall not exceed the smallest pack available in the market.

FIFTH SCHEDULE

Clause 5 (5)

MATERIALS INCLUDED IN THE DRUG TARIFF, WHEN SUPPLIED BY A HOSPITAL BOARD APPROVED BY THE DIRECTOR-GENERAL OF HEALTH

1. (1) The materials specified in subclause (4) of this clause are allowed only to the extent (if any) and for the purposes and subject to the conditions specified in this clause.

(2) In the case of an outpatient suffering from any of the following diseases in which these drugs are life-saving or essential to the wellbeing of the patient, on the recommendation of the Special Medical Committee of an approved Hospital Board, namely:

Addison's disease.

Asthma.

Hypopituitarism.

Dermatomyositis.

Disseminated lupus erthematosus.

Exfoliative dermatitis.

Pemphigus.

Periarteritis (polyarteritis) nodosa.

Scleroderma.

Sjögren's syndrome.

(3) In the case of an outpatient suffering from rheumatoid arthritis, or from any other condition approved by the Director-General of Health for the purpose of this clause, where the following conditions are fulfilled:

(a) Where the outpatient has been under observation and for a reasonable period has undergone standard methods of treatment, such as adequate rest, salicylates, or physical therapy, without relief; and

(b) Where the outpatient has been enabled to continue or to resume his normal occupation, or to undertake an alternative occupation as a result of treatment; and

(c) Where the outpatient has been or will be kept out of hospital as a result of treatment; and

(d) Where the approval of the Director-General of Health has been obtained in each case, following the receipt of a recommendation in writing from the appropriate Medical Committee of an approved Hospital Board.

(4) The materials to which this clause applies are—

Corticotrophin (ACTH) for injection.

Corticotrophin (ACTH, long acting type) for injection (Corticotrophin-Z).

Cortisone acetate tablets.

Hydrocortisone tablets.

Hydrocortisone suspension for injection.

2. The following materials are allowed on the approval of a Tuberculosis Officer:

Isoniazid.

Para-amino-salicylic acid and its salts.

Para-acetylaminobenzaldehyde thiosemicarbazone, also known as TB1, or thiacetazone.

Para-ethylsulphonylbenzaldehyde thiosemicarbazone, also known as TB3.

FIFTH SCHEDULE—*continued*

Promanide, also known as promin.

Sulfoxone sodium, also known as diasone.

Such preparations of the materials specified in this clause, and such similar substances or preparations, as are approved from time to time by the Director-General of Health.

3. Such hexamethonium salts or pentamethonium salts or other methonium compounds as are specified hereunder, and such other hexamethonium salts or pentamethonium salts or other methonium compounds as are approved from time to time by the Director-General of Health:

Hexamethonium bromide.

Hexamethonium chloride.

Hexamethonium iodide.

Hexamethonium tartrate.

Pentamethonium bromide.

Pentamethonium iodide.

Pentolinium tartrate.”

Dated at Wellington this 15th day of February 1955.

J. R. HANAN,
Minister of Health.

EXPLANATORY NOTE

[*This note is not part of the direction, but is intended to indicate its general effect.*]

This direction amends the Drug Tariff 1953, which regulates the supply of drugs and materials at the cost of the Social Security Fund.

Clause 2 substitutes a reference to the 1954 edition of the British Pharmaceutical Codex for the existing reference to the 1949 edition and 1952 supplement; but the preparations included in the 1949 edition and its supplement will continue to be included in the Drug Tariff until the end of September 1955.

Clause 4 (1) increases from ten to sixteen the number of tablets of penicillin for oral use that may be supplied on one medical prescription. Clause 4 (2) adds further drugs to those at present included in the Drug Tariff (“Second Schedule drugs”).

Clause 5 substitutes new Fourth and Fifth Schedules for the existing ones. The Fourth Schedule lists the drugs that may be supplied only when prescribed for certain diseases on a specially endorsed medical prescription. The new Fourth Schedule now includes certain antibiotic preparations (aureomycin, chloromycetin, and terramycin) which formerly could be supplied only by approved Hospital Boards under the Fifth Schedule. The new Fifth Schedule contains an extended list of diseases for which ACTH and cortisone may be supplied to outpatients by approved Hospital Boards, subject to the conditions set out in that Schedule.

Clauses 3 and 6 contain consequential amendments and revocations.

This direction comes into force on 1 March 1955.

Issued under the authority of the Regulations Act 1936.

Date of notification in *Gazette*: 17 February 1955.

These regulations are administered in the Department of Health.